Podcast Summary: unPAUSED with Dr. Mary Claire Haver

Episode Title: Female Libido in Menopause: Desire Loss, Biology & Solutions with Cindy Eckert
Release Date: February 10, 2026
Host: Dr. Mary Claire Haver
Guest: Cindy Eckert, CEO of Sprout Pharmaceuticals, creator of Addyi (“the pink pill” for women’s libido)

Episode Overview

This episode unpacks why female sexual desire is misunderstood, under-researched, and marginalized—especially during and after menopause. Dr. Mary Claire Haver and guest Cindy Eckert have an unfiltered conversation about the history, biology, and cultural taboos around women’s libido loss, the groundbreaking (and embattled) development and approval of Addyi, and what it takes to reclaim agency, research, and health solutions for women. Cindy’s journey from male sexual health innovations to pioneering female treatments brings to light systemic disparities—and hopeful change—in women’s sexual healthcare.

Key Discussion Points & Insights

1. The Silence and Stigmatization of Female Sexual Health

• Sexual health in women often gets dismissed or treated as a psychiatric/emotional issue, with very little training or conversation in medical education.

  • [00:09] Cindy Eckert: “That is the biggest misconception, though, that everything that goes wrong for women as it relates to sex is rooted in emotion and everything that goes wrong for men is rooted in biology. And that is the big dissatisfaction.”
  • [31:47] Cindy Eckert: "That is the biggest misconception, though, that everything that goes wrong for women ... is rooted in emotion. And everything that goes wrong for men is rooted in biology."

• Most doctors, even OBGYNs, are unprepared to counsel or treat women’s libido issues, often resorting to platitudes: "try relaxing or have a glass of wine" [01:40].

2. Cindy Eckert’s Journey: From Pharma Sales to Sexual Health Disruptor

• Cindy’s nomadic upbringing and business curiosity led her to pharmaceuticals, starting at Merck and moving to increasingly innovative, smaller companies [06:13].
• Her first company, Slate, focused on male sexual health (testosterone), but she quickly saw the glaring gap for women: 26 approved drugs for men’s sexual dysfunction, none for women [10:36].
• The origin story of Addyi: a "brain drug" discovered (much like Viagra) to have a positive effect on women’s sexual desire [13:52].
  • [13:36] “We are brain flow, not blood flow ... this is desire, not arousal.”

3. The Science of Female Desire & Introducing Addyi

• Addyi is not “female Viagra.” Instead, it is a non-hormonal, once-a-day pill that acts on neurotransmitters to reignite sexual desire by working in the brain, not through blood flow like Viagra [13:45].
• Loss of desire is distinct from arousal or orgasmic dysfunction; Addyi helps when desire vanishes unexpectedly, even in good relationships [15:54].
• How patients experience returning desire:
  • [16:40] “The first thing we hear is like, oh my gosh, I'm having, like, little thoughts and fantasies again ... it’s that percolating of interest.”
• Works gradually over 8 weeks; not an instant “party drug” [17:51].

4. The Battle for FDA Approval & Institutional Bias

• Addyi underwent the largest-ever women’s clinical drug study, with 13,000 participants (vs 4,000 for Viagra) and hundreds of millions invested—but the FDA initially rejected it [21:21].
• Disparity: Viagra was “fast tracked” for men in 6 months; Addyi took 6 years, two rejections, public shaming, and required triple the data [34:26, 34:40].
  • [34:40] “Men getting erections was that important. Pink pill, six years, two rejections ... three times as many patients worth of data.”
• Much of the resistance was cultural, not scientific: “Does it matter for women to have pleasure?” [27:22].
• Media and public bias:
  • Press coverage minimized the significance of treating women’s desire, mocked the “pink pill,” and patients speaking out were often disparaged or ridiculed [29:20].
  • [29:35] “You’re at a federal agency and you're opening the doors of your bedroom to tell your most private struggles. ...They're my heroes.”

5. Change Driven by Data, Women’s Voices, and Persistent Advocacy

• Patients’ testimony at FDA and public meetings was pivotal in shifting the perspective from “trivial” to real, valid need [29:23].
• Breaking institutional taboos:
  • Patient-focused drug development became a mandate—patients’ lived experience entered the regulatory process [28:49].
• After initial approval, a major pharma company acquired (and shelved) Addyi, requiring Cindy to fight to get it back and relaunch it herself [36:10].
  • [36:10] “Women couldn’t get it in the pharmacies ... I was crushed.”

6. Ongoing Hurdles: Insurance, Medical Education, and Social Attitudes

• Insurers still demand women “fail” marriage counseling before covering Addyi—an absurd double standard never applied to men [59:49].
  • [60:07] “She has to try marriage counseling—just to fail marriage counseling. ... What if she sends her a divorce decree? Does she get the medication then?”
• Coverage for male sexual health (Viagra, vasectomy) is routine; women face barriers, blame, and gatekeeping, including from within their own gender [62:30-62:48].
• Persistent medical paternalism and generational biases:
  • Many older or institutional clinicians see libido loss as inevitable or emotional and are dismissive [63:54].

7. Progress and Hope: Changing the Conversation

• Addyi’s existence and continued advocacy is shifting the conversation—now knowledge of HSDD and treatments is required for board certification in multiple specialties [46:58].
• Social media and community are helping women see they're not alone and empowering them to realize there are solutions [50:03].
• Cindy invests in and supports other female health entrepreneurs, emphasizing passion and authenticity over pitch perfection [43:23].

Notable Quotes & Memorable Moments

• On systemic bias:
  • [10:36] “There are 26 FDA approved treatment options for men to lead a more satisfying sex life, and not a single one for women.” – Cindy Eckert
• On stigma:
  • [29:38] “You're at a federal agency opening the doors of your bedroom ... and they did it because they knew if I don’t say it, it never changes.” – Cindy Eckert
  • [26:55] “Can you do that? I’m like, we’re about to find out.” – Cindy Eckert, on deciding to fight the FDA.
• On business and barriers:
  • [13:36] “We are brain flow, not blood flow ... Female Viagra is a misnomer.” – Cindy Eckert
  • [34:39] “Men getting erections was that important. Pink pill, six years, two rejections ...” – Cindy Eckert
• On cultural change:
  • [46:27] “Women are ready to invest in their own health ... If you look at the control of wealth ... you are really out of touch if you're not looking at these opportunities right now.” – Cindy Eckert
• On mentoring and pitching:
  • [43:23] “It’s so much less about the idea and so much more about who’s championing it ... the moment she started to cry was the moment I knew I was putting money in.” – Cindy Eckert

Timestamps for Key Segments

• 00:09 Debunking emotion vs. biology in male/female sexual issues
• 08:35 Start of entrepreneurial journey—founding the first company
• 10:36 Stark disparity: 26 drugs for men, zero for women
• 13:36 “Female Viagra” explained—why it’s a misnomer
• 21:19 Expensive, massive clinical trials—funding difficulties
• 23:45 FDA rejects Addyi—stinging double standards
• 26:57 Cindy’s decision to fight the FDA (and her all-in approach)
• 29:23 Patients testifying at FDA and the emotional weight of their stories
• 34:26 Six months for Viagra, six years and multiple rejections for Addyi
• 36:10 Major company shelves Addyi; Cindy fights and succeeds in getting it back
• 46:58 Now inclusion of HSDD/Addyi in specialty board exams—a sign of (slow) progress
• 59:49 Absurd insurance hoops: “Fail marriage counseling” for Addyi coverage
• 65:23 Myth to retire: “It’s men’s right to receive pleasure and women’s to deliver pleasure.”

The Pink Pill Documentary

• [65:39] The making of The Pink Pill: Sex, Drugs, and Who Has Control? explores the cultural, regulatory, and human journey behind Addyi. Cindy’s reluctance gave way to participation after seeing the honor it afforded the women who bravely spoke out.
  • [67:00] “It honors all of the women in the room that day who stood very bravely ... and they did it anyway.”

Closing Reflections & Calls to Action

• Equality and Agency:
  • [68:47] “I'm always working. What is it? ... This is my passion, and I won’t stop ... when we’re really treating women equally when it comes, not differently, equally.” – Cindy Eckert
• Why She Keeps Going:
  • [69:24] “I've decided I'm allergic to hypocrisy.” – Cindy Eckert
• Dr. Haver’s Tribute:
  • [69:29] “You were the first person in all of my training who made me look at how we treat women’s sexual desire as a medical condition and you changed my life.”

Conclusion

This episode is a masterclass in how science, social change, and stubborn advocacy can chip away at decades of neglect, misunderstanding, and bias against women’s sexual health—especially in menopause and midlife. Both Dr. Haver and Cindy Eckert offer hope that, while the barriers are real, so is the momentum for change.

Find Cindy Eckert:

• Instagram: @cindypinkceo
• Addyi: addyi.com

Find Dr. Mary Claire Haver:

• Instagram: @drmaryclaire
• thepauselife.com

If you’re interested in female sexual health, innovations in women’s medicine, or the untold stories behind new treatments, this is essential listening.